Curated News
By: NewsRamp Editorial Staff
June 05, 2025
Calidi Biotherapeutics Unveils Promising CLD-401 Data at ASCO
TLDR
- Calidi Biotherapeutics' CLD-401 offers a competitive edge in immuno-oncology with its novel CD55 receptor modification, enhancing resistance to immune clearance for systemic cancer therapy.
- Calidi Biotherapeutics advances its RedTail platform with CLD-401, incorporating a chimeric CD55 receptor to shield the virus from immune system clearance, detailed in ASCO presentation.
- Calidi Biotherapeutics' innovative CLD-401 therapy promises to improve cancer treatment outcomes, offering hope for patients with high unmet medical needs through targeted immunotherapy.
- Discover how Calidi Biotherapeutics is revolutionizing cancer treatment with CLD-401, a therapy designed to evade the immune system and target tumors more effectively.
Impact - Why it Matters
This news is significant as it highlights a breakthrough in cancer treatment, offering hope for patients with hard-to-treat cancers. Calidi Biotherapeutics' innovative approach to immunotherapy could revolutionize how cancers are treated, particularly those with high unmet medical needs. The development of therapies that can effectively target and treat metastatic cancer sites without being cleared by the immune system represents a major advancement in oncology.
Summary
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, has unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The company's innovative approach involves an enveloped form of its proprietary oncolytic virus, designed to be more resistant to immune clearance, allowing for systemic delivery and efficacy in tumor-bearing pre-clinical models. A novel genetic modification incorporating a chimeric CD55 receptor into the virus's envelope further enhances its resistance to immune system clearance, marking a significant advancement in the development of systemic oncolytic targeted immunotherapies. Calidi Biotherapeutics is at the forefront of developing a new generation of targeted immunotherapies with its proprietary Redtail platform, aiming to address high unmet medical needs in cancers such as non-small cell lung cancer and ovarian cancer. For more details, visit https://ibn.fm/EnYuL.
About Calidi Biotherapeutics Inc.: Headquartered in San Diego, California, Calidi is pioneering the development of advanced enveloped technology intended to shield the virus from immune clearance, enabling effective virotherapy delivery to tumor sites. The company's efforts are supported by TinyGems, a specialized communications platform focusing on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio at IBN. TinyGems provides comprehensive corporate communications solutions, ensuring broad reach and recognition for its clients. For more information on Calidi Biotherapeutics, visit www.CalidiBio.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Calidi Biotherapeutics Unveils Promising CLD-401 Data at ASCO
